SUDEEP PHARMA LIMITED
SUDEEPPHRM · General/Diversified · NSE
₹750
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for SUDEEPPHRM yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
65%
ROE
28.1%
Debt/Equity
0.28
WACC
11.1%
Market Cap
₹8,465 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
31.4%
Return on capital employed
EV / EBITDA
34.4×
Enterprise multiple
Debt / EBITDA
0.6×
Leverage vs earnings
Interest Coverage
40.2×
EBIT covers interest
Current Ratio
2.43×
Short-term liquidity
Asset Turnover
0.69×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
SUDEEPPHRM · last 3 annual periods
ROE
28.1%
ROCE
31.4%
Operating Margin
—
Debt / Equity
0.28×
PE
—
EV / EBITDA
—
Historical Financials
SUDEEPPHRM · Annual, last 3 years· amounts in ₹Cr unless noted
| Metric | 2023 yfinance | 2024 yfinance | 2025 yfinance | CAGR |
|---|---|---|---|---|
| Revenue | ₹426 Cr | ₹455 Cr | ₹497 Cr | +8.0% |
| EBITDA | ₹97.3 Cr | ₹187 Cr | ₹198 Cr | +42.7% |
| EBIT | ₹89.4 Cr | ₹178 Cr | ₹188 Cr | +44.8% |
| PAT | ₹62.3 Cr | ₹133 Cr | ₹139 Cr | +49.2% |
| EPS (diluted) | ₹5.52 | ₹11.79 | ₹12.28 | +49.2% |
| CFO | ₹48.4 Cr | ₹65.7 Cr | ₹48.7 Cr | +0.3% |
| CapEx | ₹-47.2 Cr | ₹-52.5 Cr | ₹-64.2 Cr | — |
| FCF | ₹1.2 Cr | ₹13.2 Cr | ₹-15.5 Cr | — |
| Total Assets | ₹420 Cr | ₹514 Cr | ₹717 Cr | +30.7% |
| Total Debt | ₹83.1 Cr | ₹78.1 Cr | ₹138 Cr | +28.7% |
| Shareholders' Equity | ₹223 Cr | ₹356 Cr | ₹493 Cr | +48.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SUDEEPPHRM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
PGHL PGHL | — | — | Pending | 3.1% | — |
 AKUMS AKUMS | — | — | Pending | 7.7% | — |
AARTIPHARM AARTIPHARM | — | — | Pending | 8.2% | — |
VIYASH VIYASH | — | — | Pending | 2.8% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SUDEEPPHRM in the last 10 years.
Risk Analysis
Volatility & drawdown
Risk profile of SUDEEPPHRM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SUDEEPPHRM →
Compare
Head-to-head with peers
Compare SUDEEPPHRM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SUDEEPPHRMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.